Key Points - Lands' End (LE) reported Q2 FY2026 results with revenue and EPS above consensus, but adjusted EPS missed expectations - The company's turnaround efforts included major IP monetization and debt paydown, but management revised EBITDA guidance downward - Lands' End saw a 3% increase in revenue in the second quarter of fiscal 2026,...
Key Points - Multiple law firms announce ongoing securities class action lawsuit against Capricor Therapeutics, Inc....
The Children's Place, Inc. (PLCE) - This analysis reviews how the stock price reacted after the...
Virco Mfg. Corporation (VIRC) - This analysis reviews how the stock price reacted after the last...
Hurco Companies, Inc. (HURC) - This analysis reviews how the stock price reacted after the last...
from Roth Capital issued a price target of $28.00 for VBNK on 2026-09-03 20:30:24.The adjusted price target was set to $28.00.At the time of the announcement, VBNK was trading at...
from Raymond James issued a price target of $20.00 for VBNK on 2026-09-03 18:44:11.The adjusted price target was set to $20.00.At the time of the announcement, VBNK was trading at...
Dana Telsey from Telsey Advisory issued a price target of $18.00 for JILL on 2026-09-03 13:46:04.The adjusted price target was set to $18.00.At the time of the announcement, JILL was...
Boobalan Pachaiyappan from Roth Capital issued a price target of $8.00 for OVID on 2026-09-03 12:01:48.The adjusted price target was set to $8.00.At the time of the announcement, OVID was...
Alpha Tau to from Barclays issued a price target of $30.00 for DRTS on 2026-09-03 09:54:22.The adjusted price target was set to $30.00.At the time of the announcement, DRTS was...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
